Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib second-line therapy in advanced hepatocellular carcinoma
CTR20132427Phase 3Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Apr 2014
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of Rivoceranib in hepatocellular carcinoma (HCC), sponsored by Hengrui Therapeutics. Started Apr 2014; status: completed.
02
Drugs
Rivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20132427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20132427.